Edgar Filing: WATSON PHARMACEUTICALS INC - Form 8-K

WATSON PHARMACEUTICALS INC Form 8-K November 05, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934

November 5, 2003

Date of Report (Date of earliest event reported)

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada 0-20045 95-3872914

(State or other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification Number)

311 Bonnie Circle Corona, California (Address of principal executive offices)

92880 (Zip Code)

(909) 493-5300

(Registrant s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 8-K

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
c. <u>Exhibits</u>
News Release for Watson Pharmaceuticals' third quarter 2003 results dated November 5, 2003.
Item 12. Results of Operations and Financial Condition.
On November 5, 2003, Watson Pharmaceuticals, Inc. (the Company) issued a news release announcing its financial results for the third quarter ended September 30, 2003. A copy of the Company s news release is attached hereto as Exhibit 99.1.
2

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 5, 2003. WATSON PHARMACEUTICALS, INC.

By: /s/ Charles P. Slacik

Charles P. Slacik

Executive Vice President and Chief Financial Officer

3